;PMID: 745599
;source_file_2660.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..44] = [t:0..44]
;1)sentence:[e:50..153] = [t:50..153]
;2)section:[e:157..210] = [t:157..210]
;3)sentence:[e:214..433] = [t:214..433]
;4)sentence:[e:434..508] = [t:434..508]
;5)sentence:[e:509..709] = [t:509..709]
;6)sentence:[e:710..810] = [t:710..810]
;7)sentence:[e:811..957] = [t:811..957]
;8)sentence:[e:958..1077] = [t:958..1077]
;9)sentence:[e:1078..1363] = [t:1078..1363]
;10)sentence:[e:1364..1515] = [t:1364..1515]
;11)sentence:[e:1516..1702] = [t:1516..1702]
;12)sentence:[e:1703..1832] = [t:1703..1832]
;13)sentence:[e:1833..2000] = [t:1833..2000]
;14)section:[e:2004..2047] = [t:2004..2047]

;section 0 Span:0..44
;Mol Cell Biochem. 1978 Dec 22;22(2-3):79-91.
(SEC
  (FRAG (NNP:[0..3] Mol) (NNP:[4..8] Cell) (NNP:[9..16] Biochem) (.:[16..17] .)
        (CD:[18..22] 1978) (NNP:[23..26] Dec) (CD:[27..29] 22) (CD:[29..32] ;22)
        (-LRB-:[32..33] -LRB-) (NN:[33..36] 2-3) (-RRB-:[36..37] -RRB-)
        (::[37..38] :) (CD:[38..40] 79) (::[40..41] -) (CD:[41..43] 91)
        (.:[43..44] .)))

;sentence 1 Span:50..153
;The drug metabolism systems of liver and liver tumors: a comparison of 
;activities and characteristics.
;[54..58]:substance:"drug"
(SENT
  (NP-HLN
    (NP
      (NP (DT:[50..53] The) (NN:[54..58] drug) (NN:[59..69] metabolism)
          (NNS:[70..77] systems))
      (PP (IN:[78..80] of)
        (NP
          (NP (NN:[81..86] liver))
          (CC:[87..90] and)
          (NP (NN:[91..96] liver) (NNS:[97..103] tumors)))))
    (::[103..104] :)
    (NP
      (NP (DT:[105..106] a) (NN:[107..117] comparison))
      (PP (IN:[118..120] of)
        (NP (NNS:[122..132] activities) (CC:[133..136] and)
            (NNS:[137..152] characteristics))))
    (.:[152..153] .)))

;section 2 Span:157..210
;Strobel HW, Dignam JD, Saine SE, Fang WF, Fennell PM.
(SEC
  (FRAG (NNP:[157..164] Strobel) (NNP:[165..167] HW) (,:[167..168] ,)
        (NNP:[169..175] Dignam) (NNP:[176..178] JD) (,:[178..179] ,)
        (NNP:[180..185] Saine) (NNP:[186..188] SE) (,:[188..189] ,)
        (NNP:[190..194] Fang) (NNP:[195..197] WF) (,:[197..198] ,)
        (NNP:[199..206] Fennell) (NNP:[207..209] PM) (.:[209..210] .)))

;sentence 3 Span:214..433
;Transplantable rat liver tumors 5123 t.c., 7288 ct.c., 5123 t.c.(H) and the 
;Novikoff hepatoma have active mixed function oxidase systems capable of 
;metabolizing a variety of drug and polycyclic hydrocarbon substrates.
;[336..343]:substance:"oxidase"
;[390..394]:substance:"drug"
;[399..421]:substance:"polycyclic hydrocarbon"
;[422..432]:substance:"substrates"
(SENT
  (S
    (NP-SBJ
      (NP
        (NP (JJ:[214..228] Transplantable) (NN:[229..232] rat)
            (NN:[233..238] liver) (NNS:[239..245] tumors))
        (NP
          (NP (CD:[246..250] 5123) (NN:[251..255] t.c.))
          (,:[255..256] ,)
          (NP (CD:[257..261] 7288) (NN:[262..267] ct.c.))
          (,:[267..268] ,)
          (NP (CD:[269..273] 5123) (NN:[274..278] t.c.) (-LRB-:[278..279] -LRB-)
              (NN:[279..280] H) (-RRB-:[280..281] -RRB-))))
      (CC:[282..285] and)
      (NP (DT:[286..289] the) (NNP:[291..299] Novikoff) (NN:[300..308] hepatoma)))
    (VP (VBP:[309..313] have)
      (NP
        (NP (JJ:[314..320] active)
          (NML (VBN:[321..326] mixed) (NN:[327..335] function))
          (NN:[336..343] oxidase) (NNS:[344..351] systems))
        (ADJP (JJ:[352..359] capable)
          (PP (IN:[360..362] of)
            (S-NOM
              (NP-SBJ (-NONE-:[362..362] *))
              (VP (VBG:[364..376] metabolizing)
                (NP
                  (NP (DT:[377..378] a) (NN:[379..386] variety))
                  (PP (IN:[387..389] of)
                    (NP
                      (NP (NN:[390..394] drug)
                        (NML-1 (-NONE-:[394..394] *P*)))
                      (CC:[395..398] and)
                      (NP
                        (NML (JJ:[399..409] polycyclic)
                             (NN:[410..421] hydrocarbon))
                        (NML-1 (NNS:[422..432] substrates))))))))))))
    (.:[432..433] .)))

;sentence 4 Span:434..508
;The tumor  drug metabolism systems are at best 20% as active as rat liver.
;[445..449]:substance:"drug"
;[481..484]:quantitative-value:"20%"
(SENT
  (S
    (NP-SBJ (DT:[434..437] The) (NN:[438..443] tumor)
      (NML (NN:[445..449] drug) (NN:[450..460] metabolism))
      (NNS:[461..468] systems))
    (VP (VBP:[469..472] are)
      (ADVP (IN:[473..475] at) (JJS:[476..480] best))
      (ADJP-PRD
        (ADJP
          (NML-EXT (CD:[481..483] 20) (NN:[483..484] %))
          (RB:[485..487] as) (JJ:[488..494] active))
        (PP (IN:[495..497] as)
          (NP (NN:[498..501] rat) (NN:[502..507] liver)))))
    (.:[507..508] .)))

;sentence 5 Span:509..709
;The tumor drug  metabolism activities are induced by pretreatment with
;phenobarbital or  beta-naphthoflavone and can be inhibited with specific
;inhibitors such as carbon  monoxide or 7,8-benzoflavone.
;[519..523]:substance:"drug"
;[580..593]:substance:"phenobarbital"
;[598..617]:substance:"beta-naphthoflavone"
;[653..663]:substance:"inhibitors"
;[672..688]:substance:"carbon  monoxide"
;[692..708]:substance:"7,8-benzoflavone"
(SENT
  (S
    (NP-SBJ-1 (DT:[509..512] The) (NN:[513..518] tumor)
      (NML (NN:[519..523] drug) (NN:[525..535] metabolism))
      (NNS:[536..546] activities))
    (VP
      (VP (VBP:[547..550] are)
        (VP (VBN:[551..558] induced)
          (NP-1 (-NONE-:[558..558] *))
          (PP (IN:[559..561] by)
            (NP-LGS
              (NP (NN:[562..574] pretreatment))
              (PP (IN:[575..579] with)
                (NP (NN:[580..593] phenobarbital) (CC:[594..596] or)
                    (NN:[598..617] beta-naphthoflavone)))))))
      (CC:[618..621] and)
      (VP (MD:[622..625] can)
        (VP (VB:[626..628] be)
          (VP (VBN:[629..638] inhibited)
            (NP-1 (-NONE-:[638..638] *))
            (PP (IN:[639..643] with)
              (NP
                (NP (JJ:[644..652] specific) (NNS:[653..663] inhibitors))
                (PP (JJ:[664..668] such) (IN:[669..671] as)
                  (NP
                    (NP (NN:[672..678] carbon) (NN:[680..688] monoxide))
                    (CC:[689..691] or)
                    (NP (NN:[692..708] 7,8-benzoflavone))))))))))
    (.:[708..709] .)))

;sentence 6 Span:710..810
;Tumor drug metabolism systems appear to consist of  cytochrome P-450 and
;cytochrome P-450 reductase.
;[716..720]:substance:"drug"
;[762..778]:cyp450:"cytochrome P-450"
;[783..809]:substance:"cytochrome P-450 reductase"
(SENT
  (S
    (NP-SBJ-1 (NN:[710..715] Tumor)
      (NML (NN:[716..720] drug) (NN:[721..731] metabolism))
      (NNS:[732..739] systems))
    (VP (VBP:[740..746] appear)
      (S
        (NP-SBJ-1 (-NONE-:[746..746] *))
        (VP (TO:[747..749] to)
          (VP (VB:[750..757] consist)
            (PP-CLR (IN:[758..760] of)
              (NP
                (NP (NN:[762..772] cytochrome) (NN:[773..778] P-450))
                (CC:[779..782] and)
                (NP
                  (NML (NN:[783..793] cytochrome) (NN:[794..799] P-450))
                  (NN:[800..809] reductase))))))))
    (.:[809..810] .)))

;sentence 7 Span:811..957
;The properties of the two  protein components from tumors are highly similar
;to the corresponding  components of the liver drug metabolism system.
;[838..845]:substance:"protein"
;[934..938]:substance:"drug"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[811..814] The) (NNS:[815..825] properties))
      (PP (IN:[826..828] of)
        (NP
          (NP (DT:[829..832] the) (CD:[833..836] two) (NN:[838..845] protein)
              (NNS:[846..856] components))
          (PP (IN:[857..861] from)
            (NP (NNS:[862..868] tumors))))))
    (VP (VBP:[869..872] are)
      (ADJP-PRD (RB:[873..879] highly) (JJ:[880..887] similar)
        (PP (TO:[888..890] to)
          (NP
            (NP (DT:[891..894] the) (VBG:[895..908] corresponding)
                (NNS:[910..920] components))
            (PP (IN:[921..923] of)
              (NP (DT:[924..927] the) (NN:[928..933] liver)
                (NML (NN:[934..938] drug) (NN:[939..949] metabolism))
                (NN:[950..956] system)))))))
    (.:[956..957] .)))

;sentence 8 Span:958..1077
;Cytochrome P-450 reductase has  been at least partially purified from the
;Novikoff hepatoma and hepatoma 5123  t.c.(H).
;[958..984]:substance:"Cytochrome P-450 reductase"
(SENT
  (S
    (NP-SBJ-1
      (NML (NN:[958..968] Cytochrome) (NN:[969..974] P-450))
      (NN:[975..984] reductase))
    (VP (VBZ:[985..988] has)
      (VP (VBN:[990..994] been)
        (ADVP-EXT
          (ADVP (IN:[995..997] at) (RBS:[998..1003] least))
          (RB:[1004..1013] partially))
        (VP (VBN:[1014..1022] purified)
          (NP-1 (-NONE-:[1022..1022] *))
          (PP (IN:[1023..1027] from)
            (NP
              (NP (DT:[1028..1031] the) (NNP:[1032..1040] Novikoff)
                  (NN:[1041..1049] hepatoma))
              (CC:[1050..1053] and)
              (NP (NN:[1054..1062] hepatoma) (CD:[1063..1067] 5123)
                  (NN:[1069..1073] t.c.) (-LRB-:[1073..1074] -LRB-)
                  (NN:[1074..1075] H) (-RRB-:[1075..1076] -RRB-)))))))
    (.:[1076..1077] .)))

;sentence 9 Span:1078..1363
;The kinetic and physical properties of the tumor reductases are similar  to
;those of the liver reductase except that the Km of hepatoma 5123 t.c.(H) 
;reductase, but not of the Novikoff hepatoma reductase for NADPH, is elevated
;an  order of magnitude over the Km of the liver reductase.
;[1127..1137]:substance:"reductases"
;[1173..1182]:substance:"reductase"
;[1199..1201]:quantitative-name:"Km"
;[1228..1237]:substance:"reductase"
;[1272..1281]:substance:"reductase"
;[1286..1291]:substance:"NADPH"
;[1337..1339]:quantitative-name:"Km"
;[1353..1362]:substance:"reductase"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1078..1081] The)
        (NML
          (NML (JJ:[1082..1089] kinetic)
            (NML-2 (-NONE-:[1089..1089] *P*)))
          (CC:[1090..1093] and)
          (NML (JJ:[1094..1102] physical)
            (NML-2 (NNS:[1103..1113] properties)))))
      (PP (IN:[1114..1116] of)
        (NP (DT:[1117..1120] the) (NN:[1121..1126] tumor)
            (NNS:[1127..1137] reductases))))
    (VP (VBP:[1138..1141] are)
      (ADJP-PRD (JJ:[1142..1149] similar)
        (PP (TO:[1151..1153] to)
          (NP
            (NP (DT:[1154..1159] those))
            (PP (IN:[1160..1162] of)
              (NP (DT:[1163..1166] the) (NN:[1167..1172] liver)
                  (NN:[1173..1182] reductase))))))
      (SBAR-ADV (IN:[1183..1189] except)
        (SBAR (IN:[1190..1194] that)
          (S
            (NP-SBJ-1
              (NP (DT:[1195..1198] the) (NN:[1199..1201] Km))
              (PP
                (PP (IN:[1202..1204] of)
                  (NP
                    (NML (NN:[1205..1213] hepatoma) (CD:[1214..1218] 5123)
                         (NN:[1219..1223] t.c.) (-LRB-:[1223..1224] -LRB-)
                         (NN:[1224..1225] H) (-RRB-:[1225..1226] -RRB-))
                    (NN:[1228..1237] reductase)))
                (,:[1237..1238] ,)
                (CONJP (CC:[1239..1242] but) (RB:[1243..1246] not))
                (PP (IN:[1247..1249] of)
                  (NP (DT:[1250..1253] the) (NNP:[1254..1262] Novikoff)
                      (NN:[1263..1271] hepatoma) (NN:[1272..1281] reductase))))
              (PP (IN:[1282..1285] for)
                (NP (NN:[1286..1291] NADPH))))
            (,:[1291..1292] ,)
            (VP (VBZ:[1293..1295] is)
              (VP (VBN:[1296..1304] elevated)
                (NP-1 (-NONE-:[1304..1304] *))
                (NP-EXT
                  (NP (DT:[1305..1307] an) (NN:[1309..1314] order))
                  (PP (IN:[1315..1317] of)
                    (NP (NN:[1318..1327] magnitude))))
                (PP (IN:[1328..1332] over)
                  (NP
                    (NP (DT:[1333..1336] the) (NN:[1337..1339] Km))
                    (PP (IN:[1340..1342] of)
                      (NP (DT:[1343..1346] the) (NN:[1347..1352] liver)
                          (NN:[1353..1362] reductase)))))))))))
    (.:[1362..1363] .)))

;sentence 10 Span:1364..1515
;The mechanism for the  interaction of electron donor and electron acceptor
;with liver or tumor  reductases seems to be a sequential reaction mechanism.
;[1460..1470]:substance:"reductases"
(SENT
  (S
    (NP-SBJ-2
      (NP (DT:[1364..1367] The) (NN:[1368..1377] mechanism))
      (PP (IN:[1378..1381] for)
        (NP
          (NP (DT:[1382..1385] the) (NN:[1387..1398] interaction))
          (PP (IN:[1399..1401] of)
            (NP
              (NP (NN:[1402..1410] electron) (NN:[1411..1416] donor))
              (CC:[1417..1420] and)
              (NP (NN:[1421..1429] electron) (NN:[1430..1438] acceptor))))
          (PP (IN:[1439..1443] with)
            (NP
              (NP (NN:[1444..1449] liver)
                (NML-1 (-NONE-:[1449..1449] *P*)))
              (CC:[1450..1452] or)
              (NP (NN:[1453..1458] tumor)
                (NML-1 (NNS:[1460..1470] reductases))))))))
    (VP (VBZ:[1471..1476] seems)
      (S
        (NP-SBJ-2 (-NONE-:[1476..1476] *))
        (VP (TO:[1477..1479] to)
          (PP (VB:[1480..1482] be)
            (NP (DT:[1483..1484] a) (JJ:[1485..1495] sequential)
                (NN:[1496..1504] reaction) (NN:[1505..1514] mechanism))))))
    (.:[1514..1515] .)))

;sentence 11 Span:1516..1702
;Experiments on the  NADP-inhibition of the interaction of NADPH and
;cytochrome c with liver  reductase indicate that NADP is competitive with
;NADPH and noncompetitive with  cytochrome c.
;[1536..1540]:substance:"NADP"
;[1574..1579]:substance:"NADPH"
;[1584..1596]:cyp450:"cytochrome c"
;[1609..1618]:substance:"reductase"
;[1633..1637]:substance:"NADP"
;[1658..1663]:substance:"NADPH"
;[1689..1701]:cyp450:"cytochrome c"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[1516..1527] Experiments))
      (PP (IN:[1528..1530] on)
        (NP
          (NP (DT:[1531..1534] the) (NN:[1536..1540] NADP) (HYPH:[1540..1541] -)
              (NN:[1541..1551] inhibition))
          (PP (IN:[1552..1554] of)
            (NP
              (NP (DT:[1555..1558] the) (NN:[1559..1570] interaction))
              (PP (IN:[1571..1573] of)
                (NP
                  (NP (NN:[1574..1579] NADPH))
                  (CC:[1580..1583] and)
                  (NP (NN:[1584..1594] cytochrome) (NN:[1595..1596] c))))
              (PP (IN:[1597..1601] with)
                (NP (NN:[1602..1607] liver) (NN:[1609..1618] reductase))))))))
    (VP (VBP:[1619..1627] indicate)
      (SBAR (IN:[1628..1632] that)
        (S
          (NP-SBJ (NN:[1633..1637] NADP))
          (VP
            (VP (VBZ:[1638..1640] is)
              (ADJP-PRD (JJ:[1641..1652] competitive))
              (PP (IN:[1653..1657] with)
                (NP (NN:[1658..1663] NADPH))))
            (CC:[1664..1667] and)
            (VP
              (ADJP-PRD (JJ:[1668..1682] noncompetitive))
              (PP (IN:[1683..1687] with)
                (NP (NN:[1689..1699] cytochrome) (NN:[1700..1701] c))))))))
    (.:[1701..1702] .)))

;sentence 12 Span:1703..1832
;This result is consistent with the postulate of a sequential  reaction for
;NADPH-cytochrome P-450 reductases of liver and tumors.
;[1778..1811]:substance:"NADPH-cytochrome P-450 reductases"
(SENT
  (S
    (NP-SBJ (DT:[1703..1707] This) (NN:[1708..1714] result))
    (VP (VBZ:[1715..1717] is)
      (ADJP-PRD (JJ:[1718..1728] consistent)
        (PP (IN:[1729..1733] with)
          (NP
            (NP (DT:[1734..1737] the) (NN:[1738..1747] postulate))
            (PP (IN:[1748..1750] of)
              (NP
                (NP (DT:[1751..1752] a) (JJ:[1753..1763] sequential)
                    (NN:[1765..1773] reaction))
                (PP (IN:[1774..1777] for)
                  (NP
                    (NP
                      (NML (NN:[1778..1783] NADPH) (HYPH:[1783..1784] -)
                        (NML (NN:[1784..1794] cytochrome)
                             (NN:[1795..1800] P-450)))
                      (NNS:[1801..1811] reductases))
                    (PP (IN:[1812..1814] of)
                      (NP (NN:[1815..1820] liver) (CC:[1821..1824] and)
                          (NNS:[1825..1831] tumors)))))))))))
    (.:[1831..1832] .)))

;sentence 13 Span:1833..2000
;These data  support the conclusions that an active drug metabolism system is
;present in  liver tumors and that the tumor systems are constituted like the
;liver system.
;[1884..1888]:substance:"drug"
(SENT
  (S
    (NP-SBJ (DT:[1833..1838] These) (NNS:[1839..1843] data))
    (VP (VBP:[1845..1852] support)
      (NP
        (NP (DT:[1853..1856] the) (NNS:[1857..1868] conclusions))
        (SBAR
          (SBAR (IN:[1869..1873] that)
            (S
              (NP-SBJ (DT:[1874..1876] an) (JJ:[1877..1883] active)
                (NML (NN:[1884..1888] drug) (NN:[1889..1899] metabolism))
                (NN:[1900..1906] system))
              (VP (VBZ:[1907..1909] is)
                (ADJP-PRD (JJ:[1910..1917] present))
                (PP-LOC (IN:[1918..1920] in)
                  (NP (NN:[1922..1927] liver) (NNS:[1928..1934] tumors))))))
          (CC:[1935..1938] and)
          (SBAR (IN:[1939..1943] that)
            (S
              (NP-SBJ-1 (DT:[1944..1947] the) (NN:[1948..1953] tumor)
                        (NNS:[1954..1961] systems))
              (VP (VBP:[1962..1965] are)
                (VP (VBN:[1966..1977] constituted)
                  (NP-1 (-NONE-:[1977..1977] *))
                  (PP (IN:[1978..1982] like)
                    (NP (DT:[1983..1986] the) (NN:[1987..1992] liver)
                        (NN:[1993..1999] system))))))))))
    (.:[1999..2000] .)))

;section 14 Span:2004..2047
;PMID: 745599 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2004..2008] PMID) (::[2008..2009] :) (CD:[2010..2016] 745599)
        (NN:[2017..2018] -LSB-) (NNP:[2018..2024] PubMed) (::[2025..2026] -)
        (NN:[2027..2034] indexed) (IN:[2035..2038] for)
        (NNP:[2039..2047] MEDLINE-RSB-)))
